Varivax

BIOLOGICAL16 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), GlaxoSmithKline, Green Cross Corporation, SK Bioscience Co., Ltd., SK Chemicals Co., Ltd.

Conditions

Haemophilus Influenzae Type bImmunization; InfectionInfections, MeningococcalMeaslesMeasles-Mumps-Rubella VaccineMeasles; Mumps; RubellaMumpsNeisseria Meningitidis

Phase 1

Immune Responses to Two Dose Varivax +/- MMR-II

TerminatedNCT00258726

National Institute of Allergy and Infectious Diseases (NIAID)Measles, Mumps, Rubella +1

Start: 2005-10-31End: 2007-07-31Target: 105Updated: 2010-08-27

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

CompletedNCT02367638

Green Cross CorporationVaricella (Chicken Pox)

Start: 2015-03-31Target: 39Updated: 2017-04-27

Safety Study of NBP608 in Healthy Adult Volunteers

CompletedNCT03121638

SK Chemicals Co., Ltd.Immunization; Infection, Varicella Zoster

Start: 2012-11-30End: 2013-03-31Updated: 2017-04-20

Phase 2

The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age

CompletedNCT03114982

SK Chemicals Co., Ltd.Varicella

Start: 2016-05-31End: 2016-11-30Updated: 2017-04-14

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

RecruitingNCT05422508

Green Cross CorporationVaricella

Start: 2022-07-05End: 2027-06-30Target: 230Updated: 2024-01-24

Phase 3

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

CompletedNCT00289783

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2006-02-22End: 2008-02-26Updated: 2018-08-24

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

CompletedNCT00345683

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2007-07-31End: 2008-11-30Updated: 2016-11-29

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

CompletedNCT01681992

GlaxoSmithKlineMeasles, Measles-Mumps-Rubella Vaccine, Mumps +1

Start: 2012-10-10End: 2015-08-18Updated: 2021-01-07

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

CompletedNCT01702428

GlaxoSmithKlineMeasles, Mumps, Rubella

Start: 2012-11-09End: 2015-04-16Updated: 2019-11-25

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

CompletedNCT02184572

GlaxoSmithKlineMeasles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine

Start: 2014-08-25End: 2015-12-22Updated: 2021-01-07

Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age

CompletedNCT03114943

SK Bioscience Co., Ltd.Varicella

Start: 2016-07-14End: 2017-06-28Updated: 2019-05-08

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

CompletedNCT03621670

GlaxoSmithKlineInfections, Meningococcal

Start: 2018-07-27End: 2024-12-27Updated: 2026-02-10

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines

CompletedNCT06314724

Sinovac (Dalian) Vaccine Technology Co., Ltd.Varicella

Start: 2024-02-29End: 2024-09-06Updated: 2025-01-27

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruitingNCT06736041

Sanofi Pasteur, a Sanofi CompanyPneumococcal Immunization

Start: 2024-12-18End: 2027-05-17Updated: 2026-02-18

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

RecruitingNCT06824194

SanofiPneumococcal Immunization

Start: 2025-02-18End: 2027-05-12Target: 2320Updated: 2026-03-03

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruitingNCT06824181

SanofiPneumococcal Immunization

Start: 2025-02-27End: 2027-09-10Updated: 2026-02-13

Related Papers

408. Safety and Immunogenicity of Meningococcal Serogroup B Vaccine (4CMenB) and 13-Valent Pneumococcal Vaccine (PCV13) Administered Concomitantly with Routine Infant Vaccines (RIVs) to Healthy United States (US) Infants: A Randomized Controlled Study

Open Forum Infectious Diseases2026-01-01

Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates

The Journal of Infectious Diseases2019-07-1012 citations

Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

Journal of the Pediatric Infectious Diseases Society2019-02-2817 citations

Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study

Human Vaccines & Immunotherapeutics2018-08-1710 citations

Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.

2018-08-109 citations

Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials.

2012-08-017 citations

The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY).

2012-02-139 citations